Healthcare >> CEO Interviews >> November 2, 2009
RIK J. DEITSCH has been the President, Chief Executive Officer and a Director of Nutra Pharma since Nov. 7, 2002. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting, Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from cone snail venom, cobra venom and gila monster venom. Mr. Deitsch holds both a B.S. in chemistry and an M.S. in biochemistry from Florida Atlantic University, and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch is an Adjunct Professor and teaches several courses for Florida Atlantic University's College of Business and Continuing Education Department. Profile
TWST: Would you please tell us about Nutra Pharma?
Mr. Deitsch: Nutra Pharma (NPHC.OB), for want of a better term, is a biotechnology holding company. We seek out interesting concepts, drugs and
